AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18203079 — intervention group
Group type: EXPERIMENTAL
Intervention: T1225 0.5% eyedrops
Number of subjects: 91
Study 18203079 — intervention group
Group type: EXPERIMENTAL
Intervention: T1225 1.0% eyedrops
Number of subjects: 91
Study 18203079 — intervention group
Group type: EXPERIMENTAL
Intervention: T1225 1.5% eyedrops
Number of subjects: 91
Study 18203079 — intervention group
Group type: EXPERIMENTAL
Intervention: T1225 1.0% and 1.5% eyedrops
Number of subjects: 91
Study 16583149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hertra 1 implantation
Number of subjects: 100
Study 16583149 — intervention group
Group type: COMPARATOR
Intervention: PerFix Plug
Number of subjects: 100
Study 14695501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 4% gel (1.0 g)
Number of subjects: 49
Study 14695501 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (1.0 g of eucerin-plus cream)
Number of subjects: 49
Study 11056593 — intervention group
Group type: EXPERIMENTAL
Intervention: rhNGF, 0.1 microg/kg, subcutaneous injection 3 times per week for 48 weeks
Number of subjects: 1019
Study 11056593 — intervention group
Group type: COMPARATOR
Intervention: Placebo, subcutaneous injection 3 times per week for 48 weeks
Number of subjects: 1019
Study 8831327 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg and Sch 1.5 mg/kg (Group I)
Number of subjects: 60
Study 8831327 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg and Sch 1.5 mg/kg (Group II)
Number of subjects: 60
Study 8831327 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg, alfentanil 40 micrograms/kg, and Sch 1.5 mg/kg (Group III)
Number of subjects: 60
Study 1336347 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (4 g) and tazobactam (500 mg) every 8 h
Number of subjects: 134
Study 1336347 — intervention group
Group type: COMPARATOR
Intervention: Imipenem (500 mg) and cilastatin (500 mg) every 8 h
Number of subjects: 134
Study 1336347 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 134
Study 1336347 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 134
Study 3912620 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF plus tamoxifen (CMFT)
Number of subjects: 312
Study 3912620 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFT plus BCG vaccinations
Number of subjects: 312
Study 3912620 — intervention group
Group type: EXPERIMENTAL
Intervention: ER measurements in the primary tumor
Number of subjects: 312
Study 31494097 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 714 (8 mg/kg, 7 intravenous doses over 10 weeks)
Number of subjects: 28
Study 31494097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 10 weeks)
Number of subjects: 28
Study 29480848 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 90
Study 29480848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27542322 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) 50mg/100mg once daily for 12 weeks (n=129)
Number of subjects: 257
Study 27542322 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir (SOF) 400mg once daily plus pegylated interferon/ribavirin (PR) for 12 weeks (n=128)
Number of subjects: 257
Study 25171575 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufflation by intermittent positive-pressure breathing (IPPB) combined with manually assisted coughing (MAC)
Number of subjects: 18
Study 25171575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) combined with manually assisted coughing (MAC)
Number of subjects: 18
Study 25171575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) alone
Number of subjects: 18
Study 25171575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) combined with MAC
Number of subjects: 18
Study 25171575 — intervention group
Group type: COMPARATOR
Intervention: Insufflation-exsufflation alone
Number of subjects: 18
Study 23241571 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss after gastric bypass surgery
Number of subjects: 100
Study 20053140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0
Study 20053140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17937837 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0
Study 17937837 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 0
Study 15142328 — intervention group
Group type: EXPERIMENTAL
Intervention: Echovist‐300 without VM
Number of subjects: 71
Study 15142328 — intervention group
Group type: EXPERIMENTAL
Intervention: Echovist‐300, VM for 5 seconds
Number of subjects: 71
Study 15142328 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive short VMs after Echovist‐300 injection
Number of subjects: 71
Study 15142328 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive short VMs after agitated saline injection
Number of subjects: 71
Study 15142328 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of two or three microbubbles
Number of subjects: 71
Study 15142328 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD using Echovist‐300
Number of subjects: 71
Study 15142328 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive VM
Number of subjects: 71
Study 11206674 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg once daily for 16 weeks
Number of subjects: 160
Study 11206674 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg once daily for 16 weeks
Number of subjects: 160
Study 11206674 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 160
Study 9534010 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfluorex (3 tablets daily)
Number of subjects: 76
Study 9534010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 7831993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower neuroleptic doses in the suicide group
Number of subjects: 56
Study 7831993 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous suicide attempts
Number of subjects: 56
Study 7831993 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 56
Study 7831993 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive schizophrenic symptoms
Number of subjects: 56
Study 3049861 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied ophthalmic solution containing trimethoprim and polymyxin B (TP)
Number of subjects: 39
Study 3049861 — intervention group
Group type: COMPARATOR
Intervention: Topically applied ophthalmic solution containing trimethoprim, polymyxin B, and sulfacetamide
Number of subjects: 39
Study 29334997 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly self-monitoring of blood glucose (4-point glucose measurements before meals and bedtime)
Number of subjects: 58
Study 29334997 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 2 weeks self-monitoring of blood glucose (4-point glucose measurements before meals and bedtime)
Number of subjects: 58
Study 29334997 — intervention group
Group type: COMPARATOR
Intervention: Monthly self-monitoring of blood glucose (4-point glucose measurements before meals and bedtime)
Number of subjects: 58
Study 27729073 — intervention group
Group type: EXPERIMENTAL
Intervention: pCGS plus diacerein
Number of subjects: 148
Study 27729073 — intervention group
Group type: COMPARATOR
Intervention: pCGS plus placebo
Number of subjects: 148
Study 25023711 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided nucleoplasty
Number of subjects: 97
Study 25023711 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided nucleoplasty with nerve root injection
Number of subjects: 97
Study 25023711 — intervention group
Group type: COMPARATOR
Intervention: CT-guided transforaminal lumbar epidural injections
Number of subjects: 97
Study 24251833 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 20
Study 24251833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20883054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide conjugate vaccine Prevenar 13 (PCV13)
Number of subjects: 0
Study 20883054 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of PCV13
Number of subjects: 0
Study 20883054 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 as catch-up vaccination
Number of subjects: 0
Study 20883054 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 18833509 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute epinephrine (1 : 20 000)
Number of subjects: 40
Study 18833509 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study 16787962 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA + exercise
Number of subjects: 56
Study 16787962 — intervention group
Group type: COMPARATOR
Intervention: Placebo + exercise
Number of subjects: 56
Study 12880881 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight concerns
Number of subjects: 367
Study 12880881 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 367
Study 15465543 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOLs
Number of subjects: 153
Study 15465543 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOLs
Number of subjects: 153
Study 15465543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 153
Study 10079445 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 220
Study 10079445 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 220
Study 7673497 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiperspirant with emollient additives (20% aluminum zirconium tetrachlorohydrex glycine concentration plus water)
Number of subjects: 23
Study 7673497 — intervention group
Group type: COMPARATOR
Intervention: Emollient additives alone (placebo control)
Number of subjects: 23
Study 7673497 — intervention group
Group type: COMPARATOR
Intervention: No treatment (nontreated)
Number of subjects: 23
Study 2123882 — intervention group
Group type: EXPERIMENTAL
Intervention: buserelin/HMG
Number of subjects: 31
Study 2123882 — intervention group
Group type: COMPARATOR
Intervention: HMG
Number of subjects: 31
Study 6116607 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 5
Study 6116607 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg plus whisky 100 ml
Number of subjects: 5
Study 6116607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31860599 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI with esketamine (group E)
Number of subjects: 162
Study 31860599 — intervention group
Group type: COMPARATOR
Intervention: Propofol TCI with alfentanil (group A)
Number of subjects: 162
Study 31860599 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (E and A)
Number of subjects: 162
Study 27880064 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy (Group-CBT) for 8 weeks
Number of subjects: 51
Study 27880064 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study 25935314 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance & Commitment group Therapy (ACT-G), n=63
Number of subjects: 126
Study 25935314 — intervention group
Group type: COMPARATOR
Intervention: Waitlist, n=63
Number of subjects: 126
Study 25935314 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated patients with severe HA
Number of subjects: 126
Study 23324658 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting insecticide-treated bed nets and water filters
Number of subjects: 589
Study 23324658 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 589
Study 21362011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene protocol implemented in 7 nursing homes
Number of subjects: 14
Study 21362011 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 nursing homes)
Number of subjects: 14
Study 19761353 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral lamivudine 100 mg/day before and until at least 6 months after transplantation
Number of subjects: 32
Study 19761353 — intervention group
Group type: COMPARATOR
Intervention: High-dose chemotherapy and AHSCT without lamivudine (historical control group)
Number of subjects: 32
Study 19761353 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral lamivudine 100 mg/day
Number of subjects: 32
Study 18688944 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1000 mg) plus loperamide
Number of subjects: 207
Study 18688944 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (500 mg) plus loperamide
Number of subjects: 207
Study 18688944 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1000 mg)
Number of subjects: 207
Study 18688944 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (500 mg)
Number of subjects: 207
Study 15318711 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 fractions of 6.5 Gy each (overall dosage‐‐26 Gy) (2 fractions per week)
Number of subjects: 167
Study 15318711 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 fractions of 6.5 Gy each (overall dosage‐‐32.5 Gy) (2 fractions per week)
Number of subjects: 167
Study 15318711 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 daily fractions of 6.5 Gy each (overall dosage‐‐26 Gy)
Number of subjects: 167
Study 15318711 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 fractions (overall dosage‐‐46 Gy) (5 weekly fractions)
Number of subjects: 167
Study 15318711 — intervention group
Group type: COMPARATOR
Intervention: Standard low‐dosage fractionated irradiation
Number of subjects: 167
Study 11531213 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triglyceride emulsion
Number of subjects: 25
Study 11531213 — intervention group
Group type: COMPARATOR
Intervention: Physical mixture of medium- and long-chain triglycerides
Number of subjects: 25
Study 9763719 — intervention group
Group type: EXPERIMENTAL
Intervention: Blister packaging of antimalarial drugs
Number of subjects: 0
Study 9763719 — intervention group
Group type: COMPARATOR
Intervention: Traditional means of dispensing antimalarial drugs (paper envelope)
Number of subjects: 0
Study 9763719 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day chloroquine course in blister packs
Number of subjects: 0
Study 9763719 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-day primaquine course in blister packs
Number of subjects: 0
Study 7512805 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine treatment with dimetindene (0.2 mg/kg) and ranitidine (1.25 mg/kg)
Number of subjects: 40
Study 7512805 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving saline
Number of subjects: 40
Study 3125026 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of misoprostol
Number of subjects: 16
Study 3125026 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol
Number of subjects: 16
Study 3125026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30987883 — intervention group
Group type: EXPERIMENTAL
Intervention: 360° VR test
Number of subjects: 28
Study 30987883 — intervention group
Group type: COMPARATOR
Intervention: Match broadcast test
Number of subjects: 28
Study 30987883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both video modes
Number of subjects: 28
Study 26211735 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lavender essential oil via inhalation for 15 days
Number of subjects: 60
Study 26211735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inhalation of lavender essential oil)
Number of subjects: 60
Study 25762359 — intervention group
Group type: EXPERIMENTAL
Intervention: FDIS + metronidazole
Number of subjects: 184
Study 25762359 — intervention group
Group type: COMPARATOR
Intervention: FDIS + placebo
Number of subjects: 184
Study 25762359 — intervention group
Group type: COMPARATOR
Intervention: SRP + metronidazole
Number of subjects: 184
Study 25762359 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo
Number of subjects: 184
Study 22858212 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 25
Study 22858212 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 25
Study 20827548 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide
Number of subjects: 203
Study 19671398 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy school meal (25-30% of daily caloric intake) for two months
Number of subjects: 145
Study 19671398 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 145
Study 17453751 — intervention group
Group type: EXPERIMENTAL
Intervention: Work day
Number of subjects: 80
Study 17453751 — intervention group
Group type: COMPARATOR
Intervention: Non-work day
Number of subjects: 80
Study 17453751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both work and non-work days
Number of subjects: 80
Study 15689645 — intervention group
Group type: EXPERIMENTAL
Intervention: Store-and-forward teledermatology consult system
Number of subjects: 0
Study 15689645 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 10086815 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi consensus technique
Number of subjects: 21
Study 10086815 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi list
Number of subjects: 21
Study 7777295 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) filtering surgery
Number of subjects: 34
Study 7777295 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 50 years or younger
Number of subjects: 34
Study 7777295 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients older than 50 years of age
Number of subjects: 34
Study 7777295 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 34
Study 2577280 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (10 mg b.i.d. for 5 days)
Number of subjects: 20
Study 2577280 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg b.i.d. for 5 days)
Number of subjects: 20
Study 2577280 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockade (timolol and metoprolol)
Number of subjects: 20
Study 712004 — intervention group
Group type: EXPERIMENTAL
Intervention: Male voices
Number of subjects: 20
Study 712004 — intervention group
Group type: EXPERIMENTAL
Intervention: Female voices
Number of subjects: 20
Study 31837886 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption (drinking an extra cup of coffee per day)
Number of subjects: 227666
Study 30720034 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fresh pear consumption (2 medium-sized pears per day)
Number of subjects: 40
Study 30720034 — intervention group
Group type: COMPARATOR
Intervention: Calorie-matched control drink
Number of subjects: 40
Study 28865866 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based resistance-aerobic (RA) sequence
Number of subjects: 13
Study 28865866 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based aerobic-resistance (AR) sequence
Number of subjects: 13
Study 26034956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled intervention including mupirocin intranasally twice daily for up to 5 days, chlorhexidine-gluconate bathing for up to 5 days, and perioperative prophylaxis with vancomycin and cefazolin or cefuroxime for MRSA carriers; cefazolin or cefuroxime for others.
Number of subjects: 42534
Study 26034956 — intervention group
Group type: COMPARATOR
Intervention: Preintervention period without the bundled intervention.
Number of subjects: 42534
Study 23230306 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Number of subjects: 955
Study 23230306 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 955
Study 23230306 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical valve replacement
Number of subjects: 955
Study 21576282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (NES)
Number of subjects: 89
Study 21576282 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NTG)
Number of subjects: 89
Study 19144937 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1005
Study 19144937 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 1005
Study 16829773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing involvement in tobacco cessation
Number of subjects: 175
Study 16829773 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental research designs
Number of subjects: 175
Study 16829773 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-experimental research designs
Number of subjects: 175
Study 16829773 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive-quantitative research designs
Number of subjects: 175
Study 16829773 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive-qualitative research designs
Number of subjects: 175
Study 16829773 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses
Number of subjects: 175
Study 16829773 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analyses and systematic reviews
Number of subjects: 175
Study 16829773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing journals
Number of subjects: 175
Study 15330029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilizarov ring fixator
Number of subjects: 60
Study 15330029 — intervention group
Group type: COMPARATOR
Intervention: Monolateral articulated external fixator
Number of subjects: 60
Study 12063773 — intervention group
Group type: COMPARATOR
Intervention: Step Two diet
Number of subjects: 132
Study 12063773 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin (up to 40 mg/day)
Number of subjects: 132
Study 9304634 — intervention group
Group type: COMPARATOR
Intervention: 5 ml of local anesthetic (2% lidocaine, 0.75% bupivacaine hydrochloride, and 1500 IU of hyaluronidase)
Number of subjects: 85
Study 9304634 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 ml of local anesthetic (2% lidocaine, 0.75% bupivacaine hydrochloride, and 1500 IU of hyaluronidase)
Number of subjects: 85